{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [6, 38]}], "size": 104, "samples": [{"hash": "eQ4vHgDj316", "uri": "/contracts/eQ4vHgDj316#anda", "label": "Asset Purchase Agreement", "score": 35.5409507751, "published": true}, {"hash": "11NOSvweYXO", "uri": "/contracts/11NOSvweYXO#anda", "label": "Merger Agreement (Ani Pharmaceuticals Inc)", "score": 32.1841201782, "published": true}, {"hash": "a5Oo8eXHCPS", "uri": "/contracts/a5Oo8eXHCPS#anda", "label": "Merger Agreement (Ani Pharmaceuticals Inc)", "score": 30.1841201782, "published": true}], "snippet": "means Abbreviated New Drug Application.", "hash": "034ed286b7e3587476b1f432fa483703", "id": 1}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [9, 41]}, {"key": "approval-of", "type": "clause", "offset": [80, 91]}, {"key": "the-fda", "type": "clause", "offset": [115, 122]}], "size": 74, "samples": [{"hash": "eCvY7FJnHCM", "uri": "/contracts/eCvY7FJnHCM#anda", "label": "Sales/Marketing Agreement", "score": 31.3408622742, "published": true}, {"hash": "bKomSlgnaHv", "uri": "/contracts/bKomSlgnaHv#anda", "label": "Exclusive License and Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "4Kk5GSQUoVE", "uri": "/contracts/4Kk5GSQUoVE#anda", "label": "Exclusive License and Supply Agreement (Eton Pharmaceuticals, Inc.)", "score": 30.3442840576, "published": true}], "snippet": "means an Abbreviated New Drug Application, or similar application for marketing approval of a Product submitted to the FDA.", "hash": "f531236cb1afb35831c550d265394104", "id": 2}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [9, 41]}, {"key": "fdc-act", "type": "definition", "offset": [60, 68]}, {"key": "applicable-regulations", "type": "definition", "offset": [73, 95]}, {"key": "the-fda", "type": "clause", "offset": [122, 129]}], "size": 54, "samples": [{"hash": "6wy8MuHZv2y", "uri": "/contracts/6wy8MuHZv2y#anda", "label": "Exclusive Commercialization Agreement (Aytu Biopharma, Inc)", "score": 36.7262153625, "published": true}, {"hash": "geIQzQUWHJB", "uri": "/contracts/geIQzQUWHJB#anda", "label": "License and Supply Agreement (Aytu Bioscience, Inc)", "score": 29.5824775696, "published": true}, {"hash": "iGEPEtetxD9", "uri": "/contracts/iGEPEtetxD9#anda", "label": "License and Supply Agreement (Aytu Bioscience, Inc)", "score": 27.3134841919, "published": true}], "snippet": "means an Abbreviated New Drug Application as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA.", "hash": "60bb7f0027c51254bea20effab3687e3", "id": 3}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [9, 41]}, {"key": "pursuant-to", "type": "clause", "offset": [42, 53]}], "size": 46, "samples": [{"hash": "6bGg1rLuWSS", "uri": "/contracts/6bGg1rLuWSS#anda", "label": "Collaboration, Option and License Agreement (Exicure, Inc.)", "score": 32.882270813, "published": true}, {"hash": "8M0sXv3t3iY", "uri": "/contracts/8M0sXv3t3iY#anda", "label": "License Agreement (Ikena Oncology, Inc.)", "score": 32.1731681824, "published": true}, {"hash": "frcVjxXfl3l", "uri": "/contracts/frcVjxXfl3l#anda", "label": "Collaboration and License Agreement (Anchiano Therapeutics Ltd.)", "score": 32.0335388184, "published": true}], "snippet": "means an Abbreviated New Drug Application pursuant to 21 U.S.C. \u00a7 355(j) and 21 C.F.R. \u00a7 314.3.", "hash": "6f86c5a2b9f63d71cdfac3cb315e2389", "id": 4}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [9, 41]}, {"key": "the-fda", "type": "clause", "offset": [53, 60]}, {"key": "pursuant-to", "type": "clause", "offset": [61, 72]}, {"key": "rules-and-regulations", "type": "clause", "offset": [77, 98]}], "size": 35, "samples": [{"hash": "rzvSQc3oiO", "uri": "/contracts/rzvSQc3oiO#anda", "label": "Asset Purchase Agreement (Athenex, Inc.)", "score": 32.1622161865, "published": true}, {"hash": "4k6U3ziqeGI", "uri": "/contracts/4k6U3ziqeGI#anda", "label": "Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "52JeUX3v3xK", "uri": "/contracts/52JeUX3v3xK#anda", "label": "Development and License Agreement (Biosante Pharmaceuticals Inc)", "score": 23.8528404236, "published": true}], "snippet": "means an Abbreviated New Drug Application filed with the FDA pursuant to its rules and regulations.", "hash": "793bd88b3981e086de3862078f5615d6", "id": 5}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [9, 41]}, {"key": "the-fda", "type": "clause", "offset": [80, 87]}, {"key": "sale-of", "type": "clause", "offset": [184, 191]}, {"key": "drug-product", "type": "clause", "offset": [194, 206]}], "size": 32, "samples": [{"hash": "k1JJ8hh94Pp", "uri": "/contracts/k1JJ8hh94Pp#anda", "label": "Exclusive License Agreement", "score": 31.3408622742, "published": true}, {"hash": "90LNHjB9dYK", "uri": "/contracts/90LNHjB9dYK#anda", "label": "Exclusive License Agreement (Proteonomix, Inc.)", "score": 23.6365509033, "published": true}, {"hash": "4ylz52o8Z6a", "uri": "/contracts/4ylz52o8Z6a#anda", "label": "Exclusive License Agreement (Proteonomix, Inc.)", "score": 21.2409305573, "published": true}], "snippet": "means an Abbreviated New Drug Application filed pursuant to the requirements of the FDA, or the equivalent application in any other country or jurisdiction, required before Commercial Sale of a drug product.", "hash": "eabdf4e66d2332129f0287b5d3ff40e4", "id": 6}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [17, 49]}, {"key": "fdc-act", "type": "definition", "offset": [69, 77]}, {"key": "functional-equivalent", "type": "definition", "offset": [114, 135]}, {"key": "relating-to", "type": "definition", "offset": [136, 147]}, {"key": "applicable-to", "type": "definition", "offset": [173, 186]}, {"key": "required-by", "type": "definition", "offset": [190, 201]}, {"key": "any-non", "type": "clause", "offset": [202, 209]}, {"key": "governmental-authority", "type": "definition", "offset": [215, 237]}, {"key": "supplements-and-amendments", "type": "clause", "offset": [252, 278]}, {"key": "with-respect-to", "type": "clause", "offset": [297, 312]}, {"key": "the-foregoing", "type": "definition", "offset": [320, 333]}], "size": 26, "samples": [{"hash": "f2PdIhUgrqV", "uri": "/contracts/f2PdIhUgrqV#anda", "label": "Credit Agreement and Guaranty (BioXcel Therapeutics, Inc.)", "score": 35.8884315491, "published": true}, {"hash": "7CVS8FxWtsq", "uri": "/contracts/7CVS8FxWtsq#anda", "label": "Credit Agreement and Guaranty (Harrow, Inc.)", "score": 35.86926651, "published": true}, {"hash": "6A2f4NMgdan", "uri": "/contracts/6A2f4NMgdan#anda", "label": "Credit Agreement (Marinus Pharmaceuticals, Inc.)", "score": 35.4284744263, "published": true}], "snippet": "means (i) (x) an abbreviated new drug application (as defined in the FD&C Act) and (y) any similar application or functional equivalent relating to any new drug application applicable to or required by any non-U.S. Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to any of the foregoing.", "hash": "11fb0bd2bcb8ef6b616c4963c680feda", "id": 7}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [6, 38]}], "size": 25, "samples": [{"hash": "6H0Fkwk9Svn", "uri": "https://www.sec.gov/Archives/edgar/data/1702123/000141057825000588/crdl-20241231xex99d1.htm", "label": "Audit Committee Charter (Cardiol Therapeutics Inc.)", "score": 24.2443523407, "published": false}, {"hash": "k3rg6d75L8H", "uri": "https://www.sec.gov/Archives/edgar/data/1702123/000110465926037844/crdl-20251231xex99d1.htm", "label": "Cardiol Therapeutics Inc.", "score": 21.2436695099, "published": false}, {"hash": "k6J2FLpFO1O", "uri": "/contracts/k6J2FLpFO1O#anda", "label": "License and Purchase Agreement (Andrx Corp /De/)", "score": 21.0, "published": true}], "snippet": "means abbreviated new drug application.", "hash": "8276bfdfb5dba7a1e50408d8864a0b1b", "id": 8}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [9, 41]}, {"key": "the-fda", "type": "clause", "offset": [80, 87]}, {"key": "part-314", "type": "clause", "offset": [110, 118]}, {"key": "regulatory-approval", "type": "definition", "offset": [129, 148]}, {"key": "in-the-united-states", "type": "clause", "offset": [163, 183]}], "size": 17, "samples": [{"hash": "bsiR4rPxHZ8", "uri": "/contracts/bsiR4rPxHZ8#anda", "label": "Collaboration and License Agreement (Kronos Bio, Inc.)", "score": 34.1991767883, "published": true}, {"hash": "cJzNzgERH3g", "uri": "/contracts/cJzNzgERH3g#anda", "label": "License Agreement (BCTG Acquisition Corp.)", "score": 32.4579048157, "published": true}, {"hash": "3A4XwA0s2rj", "uri": "/contracts/3A4XwA0s2rj#anda", "label": "Research Collaboration and License Agreement (BCTG Acquisition Corp.)", "score": 32.4579048157, "published": true}], "snippet": "means an abbreviated new drug application filed pursuant to the requirements of the FDA pursuant to 21 C.F.R. Part 314 to obtain regulatory approval for a product in the United States, or the equivalent application or filing in another country (as applicable).", "hash": "971e908daf847d56c7225c32096fd51a", "id": 9}, {"snippet_links": [{"key": "abbreviated-new-drug-application", "type": "definition", "offset": [9, 41]}, {"key": "the-fda", "type": "clause", "offset": [53, 60]}, {"key": "pursuant-to-section", "type": "definition", "offset": [61, 80]}, {"key": "supplements-and-amendments", "type": "clause", "offset": [116, 142]}, {"key": "application-for-marketing-authorization", "type": "definition", "offset": [168, 207]}, {"key": "required-by", "type": "definition", "offset": [265, 276]}, {"key": "governmental-authority", "type": "definition", "offset": [306, 328]}, {"key": "the-united-states", "type": "definition", "offset": [340, 357]}], "size": 17, "samples": [{"hash": "jOs0p3pq4IO", "uri": "/contracts/jOs0p3pq4IO#anda", "label": "Credit Agreement (Esperion Therapeutics, Inc.)", "score": 37.2491444216, "published": true}, {"hash": "1bVSMirj9GC", "uri": "/contracts/1bVSMirj9GC#anda", "label": "Credit Agreement (ARS Pharmaceuticals, Inc.)", "score": 36.742641449, "published": true}, {"hash": "z3t1GLlbO9", "uri": "/contracts/z3t1GLlbO9#anda", "label": "Credit Agreement (Esperion Therapeutics, Inc.)", "score": 35.9486656189, "published": true}], "snippet": "means an abbreviated new drug application filed with the FDA pursuant to section 505(j) of the FDCA, along with all supplements and amendments thereto, and any similar application for marketing authorization of a product commonly referred to as a \u201cgeneric\u201d product required by any country, jurisdiction or Governmental Authority other than the United States.", "hash": "af581d6a4eef1a915a7c69b2360bda83", "id": 10}], "next_curs": "ClESS2oVc35sYXdpbnNpZGVyY29udHJhY3Rzci0LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiINYW5kYSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "ANDA", "size": 929, "snippet": "means Abbreviated New Drug Application.", "id": "anda", "examples": ["PENTING: PERJANJIAN INI MENGANDUNGI TERMA \u2587\u2587\u2587 SYARAT YANG DITERIMA PAKAI UNTUK KAD \u2587\u2587\u2587 AKAUN KAD <strong>ANDA</strong>.", "<strong>ANDA</strong> TIDAK BOLEH MENGGUNAKAN KAD SEBELUM TARIKH SAH (JIKA ADA) ATAU SELEPAS TARIKH SAH LAKU YANG DICETAK PADA MUKA DEPAN KAD.", "JIKA <strong>ANDA</strong> TIDAK MAHU TERIKAT DENGAN PERJANJIAN INI, POTONG DUA KAD \u2587\u2587\u2587\u2587 \u2587\u2587\u2587 KEMBALIKANNYA KEPADA KAMI.", "MELAINKAN <strong>ANDA</strong> BERBUAT DEMIKIAN, KAMI MENGANGGAP <strong>ANDA</strong> TELAH MENERIMA PERJANJIAN INI.", "Rhythm will be responsible for obtaining, at its expense, all regulatory and governmental approvals and permits necessary for Rhythm\u2019s use of any Product Developed and/or Manufactured under this Agreement, including, without limitation, IND, <strong>ANDA</strong>, and NDA submissions and any analogous submissions filed with the appropriate Authority of a country other than the United States.", "The Steering Committee shall \u2587\u2587\u2587\u2587\u2587\u2587 the collaborative relationship between the parties and shall in particular monitor the progress of the Development Program and Impax\u2019s progress with respect to the <strong>ANDA</strong> Products.", "Each payment made under this Section 6.3 shall be accompanied by a written report stating the number and description of all <strong>ANDA</strong> Products sold in the Territory during the relevant calendar quarter; a detailed breakdown of the Cost of Sales associated therewith; the gross sales associated therewith; the calculation of Net Sales thereon, including without limitation the amount of any deduction provided for in the definition of Net Sales; and the calculation of Gross Profits therefrom.", "As such, Patheon shall not assume any responsibility for the accuracy of the NDA or the <strong>ANDA</strong>, as the case may be.", "Medicis\u2019 right to receive a share of the Gross Profit under this Section 6.3 with respect to an <strong>ANDA</strong> Product shall expire, on an <strong>ANDA</strong> Product-by-<strong>ANDA</strong> Product basis, ten (10) years after the first commercial sale by Impax of such <strong>ANDA</strong> Product in the Territory after the applicable <strong>ANDA</strong> has been approved by the FDA.", "Impax shall use Diligent Efforts to obtain Regulatory Approval in the Territory for each <strong>ANDA</strong> Product."], "related": [["nda", "NDA", "NDA"], ["biologics-license-application", "Biologics License Application", "Biologics License Application"], ["drug-approval-application", "Drug Approval Application", "Drug Approval Application"], ["regulatory-approval-application", "Regulatory Approval Application", "Regulatory Approval Application"], ["marketing-approval-application", "Marketing Approval Application", "Marketing Approval Application"]], "related_snippets": [], "updated": "2026-04-05T05:49:25+00:00"}, "json": true, "cursor": ""}}